Navigation Links
Honeywell Technology Selected to Control Manufacturing Processes at Major U.S. Biotech Site
Date:3/11/2009

Solutions Will Help Drive Production Efficiency and Reliability for New Shire Human Genetic Therapies Facility

PHOENIX, March 12 /PRNewswire-FirstCall/ -- Honeywell (NYSE: HON) today announced it will help a leading specialty biopharmaceutical organization expand its research and development capabilities for creating life-saving medications. Shire Human Genetic Therapies (HGT), a business unit of Shire plc, will use several Honeywell solutions - including Experion(R) Process Knowledge System (PKS), Experion Batch Manager, the OneWireless(TM) industrial wireless network and Uniformance Process Historian Database (PHD) - to control manufacturing processes at its new $250-million production facility in Lexington, Massachusetts.

Shire HGT is committed to developing, manufacturing, and commercializing therapies for life-threatening genetic diseases. The new facility is scheduled for completion in spring 2010 and will be the largest disposable biotechnology site in the United States. This is a new concept where disposable vessels and tank liners are used to reduce the cost of cleaning and verification of process equipment. The site also will include cell-culture production, a clinical suite, and just-in-time warehousing.

"Technology that simplifies scale-up from R&D to commercialized production is critical for biotech facilities to produce as efficiently and reliably as possible," said Don Wuchterl, Director of Manufacturing, Shire Human Genetic Therapies. "Experion and OneWireless are proven to streamline operations and will provide the flexibility required for a multi-purpose facility such as ours."

Shire will use Experion as the primary control platform for the new facility. The system helps operators run production by integrating critical subsystems throughout the plant, providing a single view into the manufacturing process via Experion client operator stations. The processing capacity of the C300 controller will reduce the amount of hardware needed to automate Shire's manufacturing process, as well as reduce operating costs. Shire will also use one of the newest additions to the Experion product line, Experion Batch Manager. Introduced in 2008, Experion Batch Manager further simplifies operations by allowing manufacturers to quickly execute complex batch recipes reliably in a regulated environment.

Additionally, the OneWireless mesh network technology will allow Shire to mount controllers on moveable equipment without having to worry about cabling issues, which can help increase their production flexibility, safety and efficiency. Also, wireless remote operator stations will be used to help reduce the overall number of stations required and eliminate the need for expensive hardened enclosures in environmentally sensitive areas.

Honeywell also will provide its Uniformance Process Historian Database (PHD) technology. Uniformance will pull information from Experion and help improve operations by allowing Shire operators to quickly store, retrieve and analyze process control data. The Honeywell solutions are ideal because they adhere to stringent pharmaceutical industry regulations and will allow Shire to scale the overall process control system as it plans for future expansions.

"Our technology enables lower production costs so biopharmaceutical producers like Shire can reinvest in research and development and deliver products to market faster," said Don Maness, regional general manager for Honeywell Process Solutions. "Additional benefits include lower validation costs, faster project implementation and reduced training requirements, all of which help manufacturers achieve operational readiness from day one and drive improved business performance."

To learn more about Honeywell's Experion PKS, Experion Batch Manager, OneWireless, Uniformance PHD, and other solutions that improve performance, visit www.honeywell.com/ps.

Honeywell International is a $37 billion diversified technology and manufacturing leader, serving customers worldwide with aerospace products and services; control technologies for buildings, homes and industry; automotive products; turbochargers; and specialty materials. Based in Morris Township, N.J., Honeywell's shares are traded on the New York, London and Chicago Stock Exchanges. For additional information, please visit www.honeywell.com. Honeywell Process Solutions is part of Honeywell's Automation and Control Solutions group, a global leader in providing product and service solutions that improve efficiency and profitability, support regulatory compliance, and maintain safe, comfortable environments in homes, buildings and industry. For more information about Process Solutions, access www.honeywell.com/ps.

This release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of fact, that address activities, events or developments that we or our management intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Forward-looking statements are based on management's assumptions and assessments in light of past experience and trends, current conditions, expected future developments and other relevant factors. They are not guarantees of future performance, and actual results, developments and business decisions may differ from those envisaged by our forward-looking statements. Our forward-looking statements are also subject to risks and uncertainties, which can affect our performance in both the near- and long-term. We identify the principal risks and uncertainties that affect our performance in our Form 10-K and other filings with the Securities and Exchange Commission.

Experion(R) is a registered trademark and OneWireless(TM) is a trademark of Honeywell International Inc.


'/>"/>
SOURCE Honeywell
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Honeywell HomMed Wins 2008 Medical Design Excellence Award for Genesis DM Remote Care Device
2. Frost & Sullivan Commends Honeywell Enraf for Cutting-Edge Products and Post-Sales Support
3. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
4. Novel Technology Breaks Through Cancer Pain
5. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
6. Advanced Cell Technology Announces Proposed Financing
7. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
8. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
9. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
10. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
11. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... ... 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), a ... webinar on Performing Quality Investigations: Getting to Root Cause. This ... charge. , Incomplete investigations are still a major concern to the Regulatory Authorities ...
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
Breaking Biology Technology:
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):